BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2019; 25(19): 2365-2372 [PMID: 31148907 DOI: 10.3748/wjg.v25.i19.2365] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Wu DD, He XF, Tian C, Peng P, Chen CL, Liu XH, Pang HJ. Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment. World J Gastroenterol 2022; 28(26): 3232-3242 [DOI: 10.3748/wjg.v28.i26.3232] [Reference Citation Analysis]
2 Okamura S, Shimose S, Niizeki T, Kamachi N, Noda Y, Shirono T, Iwamoto H, Nakano M, Kuromatsu R, Koga H, Torimura T. Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma. Mol Clin Oncol 2022;16:8. [PMID: 34881028 DOI: 10.3892/mco.2021.2442] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Catalano M, Casadei-Gardini A, Vannini G, Campani C, Marra F, Mini E, Roviello G. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Rev Clin Pharmacol 2021;:1-13. [PMID: 34289756 DOI: 10.1080/17512433.2021.1958674] [Reference Citation Analysis]
4 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Takeda H, Takai A, Takahashi K, Seno H. A simplified method to quantitatively predict the effect of lenvatinib on hepatocellular carcinoma using contrast-enhanced ultrasound with perfluorobutane microbubbles. Quant Imaging Med Surg 2021;11:2766-74. [PMID: 34079740 DOI: 10.21037/qims-20-965] [Reference Citation Analysis]
5 Takahashi K, Kim J, Takahashi A, Hashimoto S, Doi M, Furuya K, Hashimoto R, Owada Y, Ogawa K, Ohara Y, Akashi Y, Hisakura K, Enomoto T, Shimomura O, Noguchi M, Oda T. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report. World J Hepatol 2021; 13(3): 384-392 [PMID: 33815680 DOI: 10.4254/wjh.v13.i3.384] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
6 Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals (Basel) 2021;14:36. [PMID: 33418941 DOI: 10.3390/ph14010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 McGregor H, Brunson C, Woodhead G, Khan A, Hennemeyer C, Patel M. Quantitative Assessment of the Hemodynamic Effects of Intra-Arterial Nitroglycerin on Hepatocellular Carcinoma using Two-Dimensional Perfusion Angiography. J Vasc Interv Radiol 2021;32:198-203. [PMID: 33279371 DOI: 10.1016/j.jvir.2020.10.023] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Komatsu S, Yano Y, Sofue K, Kido M, Tanaka M, Kuramitsu K, Awazu M, Gon H, Yamamoto A, Yanagimoto H, Toyama H, Kodama Y, Murakami T, Fukumoto T. Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis. HPB 2020;22:1450-6. [DOI: 10.1016/j.hpb.2020.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188391. [PMID: 32659252 DOI: 10.1016/j.bbcan.2020.188391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
10 Mohamed TM, Ji-bin LM, John REP. Recent Advances in Microbubble-Augmented Cancer Therapy. Advanced Ultrasound in Diagnosis and Therapy 2020;4:155. [DOI: 10.37015/audt.2020.200055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, Fujishiro M. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol Res 2020;50:374-81. [DOI: 10.1111/hepr.13452] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]